Testing for Pancreatic Cancer
Transforming Pancreatic Cancer Screening with Proactive Diagnostics
Pancreatic cancer is one of the most aggressive and difficult‑to‑detect cancers in the UK. Early symptoms are vague, subtle, or completely absent, meaning most cases are diagnosed only once the disease has already advanced. Signs such as abdominal discomfort, back pain, unexplained weight loss, or digestive changes often appear late and can easily be mistaken for benign conditions.
Traditional diagnostic methods typically identify pancreatic cancer only after structural abnormalities are visible on imaging or after a tumour has grown large enough to cause symptoms.
Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before visible changes occur.
The HrC test represents a new generation of pancreatic cancer screening — one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into pancreatic cancer risk than conventional methods alone.
Current Methods for Diagnosing Pancreatic Cancer
Pancreatic cancer diagnosis in the UK typically involves several established tools used within NHS and private healthcare settings:
Ultrasound
Often used as an initial scan, but the pancreas is difficult to visualise due to its deep location in the abdomen.
CT or MRI Scan
Cross‑sectional imaging used to detect masses, ductal changes, or spread. These tools only identify pancreatic cancer once structural changes have occurred.
Endoscopic Ultrasound (EUS)
A more invasive procedure that uses an endoscope to obtain detailed images of the pancreas.
Biopsy
Tissue samples collected via endoscopy or needle aspiration to confirm malignancy.
These methods are essential in improving outcomes, yet they remain reactive — “they detect cancer only after visible changes occur”.
Limitations of Conventional Pancreatic Cancer Screening
Despite their value, traditional diagnostic tools present several challenges that make early detection extremely difficult:
Symptoms Are Often Absent or Misleading
Early pancreatic cancer symptoms mimic common digestive issues such as:
- Indigestion
- Bloating
- Mild abdominal discomfort
- Fatigue
This leads to delayed referrals and missed early‑stage cases.
No Routine Screening Programme
Unlike breast or cervical cancer, there is no national screening programme for pancreatic cancer. Most diagnoses occur only after symptoms worsen.
Deep Anatomical Location
The pancreas sits behind the stomach, making it difficult to image clearly. Small tumours are often missed.
Detection Threshold
Imaging can only identify pancreatic cancer once tumours reach a detectable size. Molecular changes may occur long before these abnormalities are visible.
Reactive Rather Than Proactive
Conventional tests identify pancreatic cancer only after structural abnormalities form, leaving a diagnostic gap during the earliest molecular stages.
False Reassurance
Normal blood tests or early imaging do not always rule out pancreatic cancer, especially in slow‑growing or early‑stage disease.
These limitations highlight the need for a diagnostic tool that identifies cancer risk before visible abnormalities develop.
Why Traditional Blood‑Based Biopsies Cannot Reliably Detect Pancreatic Cancer
Blood‑based biopsies (liquid biopsies) have shown promise for some cancers — but they fall short for pancreatic cancer due to several biological and technical limitations:
Pancreatic Tumours Shed Very Little DNA Into the Bloodstream
Early pancreatic tumours are small and deep within the abdomen.
This means:
- Very little tumour DNA enters the bloodstream
- Standard liquid biopsies often return false‑negative results
Circulating Tumour DNA (ctDNA) Levels Are Extremely Low
Pancreatic cancer cells:
- Shed less DNA
- Shed inconsistently
- Shed only at later stages
This makes ctDNA‑based detection unreliable.
Pancreatic Cancer Mutations Are Diverse
There is no single mutation or biomarker that reliably identifies pancreatic cancer.
Most liquid biopsies rely on:
- Mutation panels
- Tumour‑specific DNA fragments
But pancreatic cancer’s genetic variability means these panels often miss early disease.
Tumours Grow in a Dense, Fibrotic Environment
Pancreatic tumours are surrounded by thick stromal tissue, which:
- Traps tumour DNA
- Reduces shedding into the bloodstream
- Makes early detection extremely difficult
Early‑Stage Disease Is Almost Invisible to Liquid Biopsy
Because early pancreatic cancer produces:
- Minimal tumour DNA
- No consistent biomarkers
- No solid mass shedding
Traditional blood biopsies cannot reliably detect it.
The HrC Test: A Breakthrough in Early Pancreatic Cancer Detection
The HrC test overcomes the limitations of traditional blood biopsies by focusing on Cancer Stem Cells (CSCs) — the earliest biological drivers of cancer.
Instead of searching for tumour DNA (which may not be present), the HrC test isolates and analyses CSCs circulating in the bloodstream. These cells appear before tumours form, enlarge, or shed DNA.
A simple 12ml blood sample enables the HrC test to deliver:
A 12–18 Month Early Warning Window
Detection of cancer‑initiating molecular activity long before conventional screening can identify abnormalities.
High Sensitivity and Clear Results
With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
Reliable “Safe Zone” Assessment
A clear indication of “no risk” offers reassurance that pancreatic cancer is not present and is unlikely to develop within the next year.
A Non‑Invasive Alternative That Could Improve Early Detection
Because the HrC test requires only a blood sample, it avoids:
- Delayed referrals
- Invasive endoscopic procedures
- Anxiety associated with vague symptoms
- The wait‑and‑see approach often used in early pancreatic cancer cases
This has the potential to significantly increase early detection rates and reduce diagnostic delays.
This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.
Comprehensive Cancer Screening Through a Single Test
Pan‑Cancer Detection for Complete Health Protection
Although this document focuses on pancreatic cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.
Key Advantages Include:
- Holistic Health Monitoring
Simultaneous assessment of pancreatic cancer risk alongside other major cancers such as Bladder, Bowel, Breast, Cervical, Kidney, Leukaemia, Liver, Lung, Ovarian, and Prostate. - Actionable Insights
Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies. - One Test, Broad Coverage
A single, non‑invasive test that enhances long‑term health planning and peace of mind.
Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.
About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here